Use of selective-serotonin reuptake inhibitors and platelet aggregation inhibitors among individuals with co-occurring atherosclerotic cardiovascular disease and depression or anxiety

SAGE Open Medicine

Volumn 4, Issue , 2016, Pages

  Thornton, J Douglas ^a   Agarwal, Parul ^a   Sambamoorthi, Usha ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Drug interaction; Pharmacoepidemiology drug safety; Survey research

Indexed keywords

ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CITALOPRAM; CLOPIDOGREL; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PRASUGREL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TICAGRELOR; TICLOPIDINE;

ADULT; AGED; ANXIETY; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CROSS-SECTIONAL STUDY; DEPRESSION; DIABETES MELLITUS; DRUG INTERACTION; EDUCATIONAL STATUS; FEMALE; HEALTH BEHAVIOR; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIAL STATUS;

EID: 85047550817     PISSN: None     EISSN: 20503121     Source Type: Journal    
DOI: 10.1177/2050312116682255     Document Type: Article

References (46)

1. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008; 118(17): 1768-1775.
2. Todaro JF, Shen BJ, Raffa SD, et al. Prevalence of anxiety disorders in men and women with established coronary heart disease. J Cardiopulm Rehabil Prev 2007; 27(2): 86-91.
3. Tully PJ and Cosh SM. Generalized anxiety disorder prevalence and comorbidity with depression in coronary heart disease: a meta-analysis. J Health Psychol 2013; 18(12): 1601-1616.
4. Kessler RC, Aguilar-Gaxiola S, Alonso J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psichiatr Soc 2009; 18(1): 23-33.
5. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiat 2005; 62(6): 617-627.
6. Egede LE. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. Gen Hosp Psychiatry 2007; 29(5): 409-416.
7. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124(22): 2458-2473.
8. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 2013; 127(13): 1425-1443.
9. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124(23): 2574-2609.
10. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124(23): 2610-2642.
11. Sanofi-Aventis/Bristol-Myers Squibb. Plavix (package insert). New York: Sanofi-Aventis/Bristol-Myers Squibb, 2010.
12. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494-502.
13. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl.): e637S-e668S.
14. Ursano RJ, Bell C, Eth S, et al. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 2004;161(11 Suppl): 3-31.
15. Koran LM, Hanna GL, Hollander E, Nestadt G and Simpson HB, American Psychiatric A. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007;164(7 Suppl): 5-53.
16. Stein MB, Goin MK, Pollack MH, et al. American Psychiatric Association practice guideline for the treatment of patients with panic disorder, 2nd edition, 2009, http://psychiatryonline. org/pb/assets/raw/sitewide/practice_guidelines/guidelines/ panicdisorder.pdf
17. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62(7): 792-798.
18. GlaxoSmithKline. Paxil (package insert). Research Triangle Park, NC: GlaxoSmithKline, 2006.
19. Pfizer. Zoloft (package insert). New York: Pfizer, 2003.
20. Lin CC, Hu HY, Luo JC, et al. Risk factors of gastrointestinal bleeding in clopidogrel users: a nationwide population-based study. Aliment Pharmacol Ther 2013; 38(9): 1119-1128.
21. Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183(16): 1835-1843.
22. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav 1995; 36(1): 1-10.
23. American College of Cardiology and American Heart Association. ASCVD risk estimator, 2014, http://tools.acc.org/ ASCVD-Risk-Estimator/
24. Agency for Healthcare Research and Quality. MEPS: survey background. Medical Expenditure Panel Survey, 2009, http:// meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp, 2016
25. Agency for Healthcare Research and Quality. MEPS HC-160A: 2013 prescribed medicines, 2015, http://meps. ahrq.gov/mepsweb/data_stats/download_data/pufs/h160a/ h160adoc.shtml
26. Fan J, Arruda-Olson AM, Leibson CL, et al. Billing code algorithms to identify cases of peripheral artery disease from administrative data. J Am Med Inform Assoc 2013; 20(e2): e349-e354.
27. Kempf J, Buysman E and Brixner D. Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting. Am Health Drug Benefits 2011; 4(6): 353-361.
28. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 2014; 311(14): 1406-1415.
29. Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002; 33(4): 901-906.
30. American Diabetes Association. Statistics about diabetes, 2016, http://www.diabetes.org/diabetes-basics/statistics/2016
31. Centers for Disease Control and Prevention. Trends in current cigarette smoking among high school students and adults, United States, 1965-2011. Smoking and Tobacco Use, 2013, http:// www.cdc.gov/tobacco/data_statistics/tables/trends/cig_smoking/
32. Centers for Disease Control and Prevention. Current cigarette smoking among adults-United States, 2005-2014. Morb Mortal Wkly Rep 2015; 64(44): 1233-1240.
33. Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004; 164(21): 2367-2370.
34. The British Psychological Society & The Royal College of Psychiatrists. Depression: the treatment and management of depression in adults. (Updated Edition). Leicester: The British Psychological Society & The Royal College of Psychiatrists, 2010.
35. Post-Myocardial Infarction Depression Clinical Practice Guideline Panel. AAFP guideline for the detection and management of post-myocardial infarction depression. Ann Fam Med 2009; 7(1): 71-79.
36. Marcus SC and Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiat 2010; 67(12): 1265-1273.
37. Mohr DC, Ho J, Duffecy J, et al. Perceived barriers to psychological treatments and their relationship to depression. J Clin Psychol 2010; 66(4): 394-409.
38. Garfield RL. Mental health financing in the United States: a primer, 2013, https://kaiserfamilyfoundation.files.wordpress. com/2013/01/8182.pdf
39. Mohebali D, Kaplan D, Carlisle M, et al. Alterations in platelet function during aging: clinical correlations with thromboinflammatory disease in older adults. J Am Geriatr Soc 2014; 62(3): 529-535.
40. Diefenbach GJ and Goethe J. Clinical interventions for late-life anxious depression. Clin Interv Aging 2006; 1(1): 41-50.
41. Fortin M, Soubhi H, Hudon C, et al. Multimorbidity’s many challenges. BMJ 2007; 334(7602): 1016-1017.
42. Boyd CM and Fortin M. Future of multimorbidity research: how should understanding of multimorbidity inform health system design? Public Health Rev 2011; 33(2): 451-474.
43. Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007; 370(9590): 851-858.
44. Parekh AK, Goodman RA, Gordon C, et al. Managing multiple chronic conditions: a strategic framework for improving health outcomes and quality of life. Public Health Rep 2011; 126(4): 460-471.
45. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46(1): 27-31.
46. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009; 32(4): 531-540.